Currently, there are 168.63M common shares owned by the public and among those 80.94M shares have been available to trade.
The company’s stock has a 5-day price change of -11.79% and -34.27% over the past three months. DNUT shares are trading -35.06% year to date (YTD), with the 12-month market performance down to -33.47% lower. It has a 12-month low price of $9.98 and touched a high of $17.84 over the same period. DNUT has an average intraday trading volume of 2.74 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -11.66%, -16.71%, and -24.42% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Krispy Kreme Inc (NASDAQ: DNUT) shares accounts for 36.91% of the company’s 168.63M shares outstanding.
It has a market capitalization of $1.65B and a beta (3y monthly) value of 1.41. The earnings-per-share (ttm) stands at -$0.27. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.04% over the week and 4.02% over the month.
Earnings per share for the fiscal year are expected to increase by 3.29%, and 47.39% over the next financial year. EPS should grow at an annualized rate of 16.10% over the next five years, compared to -24.46% over the past 5-year period.
Looking at the support for the DNUT, a number of firms have released research notes about the stock. Truist stated their Buy rating for the stock in a research note on June 10, 2024, with the firm’s price target at $13-$15. JP Morgan coverage for the Krispy Kreme Inc (DNUT) stock in a research note released on June 03, 2024 offered a Overweight rating with a price target of $14. Piper Sandler was of a view on April 05, 2024 that the stock is Overweight, while CapitalOne gave the stock Equal Weight rating on January 22, 2024, issuing a price target of $16. JP Morgan on their part issued Neutral rating on November 20, 2023.
